Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Trial Sites
Back to Top
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase II | Treatment | Active | 1 to 17 | Pharmaceutical / Industry | CA180-372 2011-001123-20, AALL1122, NCT01460160 |
Summary
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)
- Age >1 year and < less than 18 years old
- Induction chemotherapy ≤ 14 days according to institutional standard of care
- Adequate liver, renal and cardiac function
Exclusion Criteria:
- Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor
- Extramedullary involvement of the testicles
- Active systemic bacterial, fungal or viral infection
- Down syndrome
Trial Lead Organizations/Sponsors
Bristol-Myers Squibb Company - New York
Children's Oncology GroupEsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
| Bristol-Myers Squibb | ![]() | Study Director |
| For participation information at a USA site use a phone number below. For site information outside the USA please email: | ![]() | |
| Email: Clinical.Trials@bms.com | ||
Trial Sites
| U.S.A. | |||
| Alabama | |||
| Birmingham | |||
| UAB Comprehensive Cancer Center | |||
| Alyssa T Reddy, Site 077 | Ph: 205-939-9285 | ||
| Arkansas | |||
| Little Rock | |||
| Arkansas Cancer Research Center at University of Arkansas for Medical Sciences | |||
| David L Becton, Site 098 | Ph: 501-364-5650 | ||
| California | |||
| Loma Linda | |||
| Antranik Agop Bedros | |||
| Antranik Agop Bedros, Site 099 | Ph: 909-558-4050 | ||
| Long Beach | |||
| Miller Children's Hospital Long Beach | |||
| Amanda Termuhlen, Site 046 | Ph: 562-933-8600 | ||
| Los Angeles | |||
| Childrens Hospital Los Angeles | |||
| Weili Sun, Site 014 | Ph: 323-361-8186 | ||
| Orange | |||
| Children's Hospital of Orange County | |||
| Violet Shen, Site 019 | Ph: 714-516-4348 | ||
| Palo Alto | |||
| Lpch & Sumc | |||
| Neyssa Marina, Site 036 | Ph: 650-723-5535 | ||
| Roseville | |||
| Kaiser Medical Center | |||
| Steven Bergstrom, Site 101 | Ph: 916-474-2170 | ||
| Colorado | |||
| Aurora | |||
| Children's Hospital Colorado Center for Cancer and Blood Disorders | |||
| Kelly Maloney, Site 072 | Ph: 720-777-6673 | ||
| Connecticut | |||
| Hartford | |||
| Connecticut Children's Medical Center | |||
| Michael Isakoff, Site 025 | Ph: 860-545-9630 | ||
| Delaware | |||
| Wilmington | |||
| Alfred I. duPont Hospital for Children | |||
| Christopher N Frantz, Site 008 | Ph: 302-651-5500 | ||
| District of Columbia | |||
| Washington | |||
| Children's National Medical Center | |||
| Jeffrey Dome, Site 018 | Ph: 202-476-2800 | ||
| Florida | |||
| Fort Myers | |||
| Lee Cancer Care of Lee Memorial Health System | |||
| Emad Salman, Site 034 | Ph: 239-343-5333 | ||
| Jacksonville | |||
| Nemours Children's Clinic | |||
| Eric Sandler, Site 049 | Ph: 904-697-3793 | ||
| Orlando | |||
| M.D. Anderson Cancer Center at Orlando | |||
| Vincent Giusti, Site 037 | Ph: 321-841-1859 | ||
| Nemours Children'S Clinic - Orlando | |||
| Ramamoorthy Nagasubramanian, Site 050 | Ph: 407-650-7230 | ||
| St. Petersburg | |||
| All Children's Hospital | |||
| Gregory Alan Hale, Site 009 | Ph: 727-747-2423 | ||
| Illinois | |||
| Chicago | |||
| Ann and Robert H. Lurie Children's Hospital of Chicago | |||
| Nobuko Hijiya, Site 022 | Ph: 773-880-4562 | ||
| Springfield | |||
| Simmons Cooper Cancer Institute | |||
| Gregory Brandt, Site 067 | Ph: 217-545-7377 | ||
| Indiana | |||
| Indianapolis | |||
| Children'S Center For Cancer And Blood Diseases | |||
| Bassem Razzouk, Site 062 | Ph: 317-338-4673 | ||
| James Whitcomb Riley Hospital For Children | |||
| Robert J Fallon, Site 030 | Ph: 317-944-8784 | ||
| Massachusetts | |||
| Boston | |||
| Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute | |||
| Lewis Silverman, Site 104 | Ph: 617-632-6191 | ||
| Michigan | |||
| Detroit | |||
| Children's Hospital of Michigan | |||
| Meret Henry, Site 105 | Ph: 313-745-5649 | ||
| Mississippi | |||
| Jackson | |||
| Univ Of Mississippi Med Ctr | |||
| Gail Megason, Site 085 | Ph: 601-984-5220 | ||
| Missouri | |||
| Kansas City | |||
| Children's Mercy Hospital | |||
| Maxine Hetherington, Site 073 | Ph: 816-234-3265 | ||
| St. Louis | |||
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | |||
| Robert Hayashi, Site 092 | Ph: 314-454-6018 | ||
| Nevada | |||
| Las Vegas | |||
| Children's Specialty Center of Nevada | |||
| Jonathan Bernstein, Site 051 | Ph: 702-384-0013 | ||
| New Jersey | |||
| Hackensack | |||
| Hackensack University Medical Center Cancer Center | |||
| Burton Elliot Appel, Site 029 | Ph: 201-996-5437 | ||
| Morristown | |||
| Goryeb Children'S Hospital | |||
| Steven Halpern, Site 097 | Ph: 973-971-6720 | ||
| Paterson | |||
| St. Joseph's Hospital and Medical Center | |||
| Mary Ann Bonilla, Site 060 | Ph: 973-754-3349 | ||
| New York | |||
| Syracuse | |||
| SUNY Upstate Medical University Hospital | |||
| Karol H. Kerr, Site 070 | Ph: 315-464-5294 | ||
| Valhalla | |||
| New York Medical College | |||
| Mehmet Ozkaynak, Site 109 | Ph: 914-594-3062 | ||
| North Carolina | |||
| Charlotte | |||
| Levine Children's Hospital | |||
| Joel Kaplan, Site 011 | Ph: 704-381-9900 | ||
| Ohio | |||
| Cincinnati | |||
| Cincinnati Children's Hospital Medical Center | |||
| Maureen O'Brien, Site 023 | Ph: 513-803-1678 | ||
| Columbus | |||
| Nationwide Children's Hospital | |||
| Laura T. Martin, Site 048 | Ph: 614-722-3552 | ||
| Dayton | |||
| The Children'S Medical Center Of Dayton | |||
| Emmett Broxson, Site 017 | Ph: 937-641-3111 | ||
| Toledo | |||
| Mercy Children's Hospital | |||
| Rama Jasty, Site 115 | Ph: 419-251-8223 | ||
| Oklahoma | |||
| Oklahoma City | |||
| Oklahoma University Cancer Institute | |||
| Rene Y Mcnall-Knapp, Site 089 | Ph: 405-271-5311 | ||
| Oregon | |||
| Portland | |||
| Legacy Emanuel Hospital and Health Center and Children's Hospital | |||
| Janice F Olson, Site 035 | Ph: 503-276-9300 | ||
| Pennsylvania | |||
| Danville | |||
| Geisinger Cancer Institute at Geisinger Health | |||
| Jeffrey Taylor, Site 007 | Ph: 570-271-6848 | ||
| Hershey | |||
| Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center | |||
| John Kuttesch, Site 053 | Ph: 717-531-6012 | ||
| Philadelphia | |||
| Children's Hospital of Philadelphia | |||
| Richard D Aplenc, Site 015 | Ph: 267-426-7252 | ||
| Pittsburgh | |||
| Children's Hospital of Pittsburgh of UPMC | |||
| A. Kim Ritchey, Site 016 | Ph: 412-692-5949 | ||
| Tennessee | |||
| Knoxville | |||
| East Tennessee Children's Hospital | |||
| Ray Pais, Site 028 | Ph: 865-541-8266 | ||
| Texas | |||
| Austin | |||
| Dell Children's Medical Center of Central Texas | |||
| Sharon K Lockhart, Site 112 | Ph: 512-628-1900 | ||
| Corpus Christi | |||
| Driscoll Children's Hospital | |||
| Cris Johnson, Site 027 | Ph: 361-694-5311 | ||
| Dallas | |||
| Ut Southwestern | |||
| Naomi Winick, Site 091 | Ph: 214-648-2912 | ||
| Fort Worth | |||
| Cook Children's Medical Center - Fort Worth | |||
| Kelly Vallance, Site 026 | Ph: 682-885-1904 | ||
| Houston | |||
| Baylor College Of Med/Tx Chldrns Cancer & Hem Ctrs. | |||
| Maria Gramatges, Site 010 | Ph: 832-824-4678 | ||
| Temple | |||
| Scott and White Cancer Institute | |||
| Guy Grayson, Site 063 | Ph: 254-724-5382 | ||
| Virginia | |||
| Norfolk | |||
| Children'S Hosp-Kings Daughter | |||
| Eric Lowe, Site 020 | Ph: 757-668-7243 | ||
| Wisconsin | |||
| Green Bay | |||
| St Vincent Hospital | |||
| John R Hill, Site 061 | Ph: 920-433-8670 | ||
| Milwaukee | |||
| Medical College of Wisconsin Cancer Center | |||
| Richard Tower, Site 045 | Ph: 414-456-4170 | ||
| Australia | |||
| Perth | |||
| Local Institution | |||
| Site 132 | |||
| Queensland | |||
| Herston | |||
| Local Institution | |||
| Site 130 | |||
| Canada | |||
| Ontario | |||
| London | |||
| Local Institution | |||
| Site 120 | |||
| Quebec | |||
| Montreal | |||
| Local Institution | |||
| Site 125 | |||
| Site 119 | |||
| Italy | |||
| Bologna | |||
| Local Institution | |||
| Site 146 | |||
| Cagliari | |||
| Local Institution | |||
| Site 141 | |||
| Catania | |||
| Local Institution | |||
| Site 133 | |||
| Firenze | |||
| Local Institution | |||
| Site 137 | |||
| Monza (Mb) | |||
| Local Institution | |||
| Site 134 | |||
| Napoli | |||
| Local Institution | |||
| Site 142 | |||
| Palermo | |||
| Local Institution | |||
| Site 139 | |||
| Roma | |||
| Local Institution | |||
| Site 145 | |||
| Torino | |||
| Local Institution | |||
| Site 143 | |||
| Trieste | |||
| Local Institution | |||
| Site 135 | |||
| Puerto Rico | |||
| San Juan | |||
| Local Institution | |||
| Site 096 | |||
| United Kingdom | |||
| Birmingham | |||
| Local Institution | |||
| Site 148 | |||
| Manchester | |||
| Local Institution | |||
| Site 152 | |||
| Newcastle | |||
| Local Institution | |||
| Site 153 | |||
| Nottingham | |||
| Local Institution | |||
| Site 163 | |||
| Sheffield | |||
| Local Institution | |||
| Site 166 | |||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01460160
Information obtained from ClinicalTrials.gov on December 19, 2012
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top

